AQR Capital Management LLC Purchases 74,949 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

AQR Capital Management LLC raised its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 16.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 536,781 shares of the biopharmaceutical company’s stock after buying an additional 74,949 shares during the quarter. AQR Capital Management LLC’s holdings in Intra-Cellular Therapies were worth $44,832,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. GAMMA Investing LLC boosted its position in Intra-Cellular Therapies by 46.3% in the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 240 shares during the last quarter. Venturi Wealth Management LLC purchased a new position in shares of Intra-Cellular Therapies during the 4th quarter valued at approximately $96,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Intra-Cellular Therapies in the third quarter valued at about $97,000. Covestor Ltd boosted its holdings in Intra-Cellular Therapies by 15.9% in the 4th quarter. Covestor Ltd now owns 2,099 shares of the biopharmaceutical company’s stock worth $175,000 after buying an additional 288 shares during the last quarter. Finally, Barlow Wealth Partners Inc. purchased a new stake in shares of Intra-Cellular Therapies during the fourth quarter worth approximately $184,000. 92.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ITCI has been the topic of a number of research reports. Canaccord Genuity Group lowered shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and raised their target price for the stock from $119.00 to $132.00 in a research note on Friday, January 31st. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $132.00 price objective (up previously from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. Needham & Company LLC reissued a “hold” rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. Cantor Fitzgerald reiterated a “neutral” rating and issued a $132.00 target price on shares of Intra-Cellular Therapies in a report on Wednesday, April 2nd. Finally, Leerink Partnrs downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Eleven analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $109.70.

Intra-Cellular Therapies Stock Performance

ITCI stock opened at $131.87 on Friday. The company has a market capitalization of $14.05 billion, a P/E ratio of -151.57 and a beta of 0.69. The business has a 50 day simple moving average of $131.49 and a 200-day simple moving average of $110.01. Intra-Cellular Therapies, Inc. has a twelve month low of $64.09 and a twelve month high of $131.98.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The business had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. Research analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.